期刊文献+

转染VEGF-ASODN对胃癌细胞Survivin表达的影响

Effects of VEGF Antisense Oligonucleotide on Expression of Survivin in Gastric Cancer Cells
下载PDF
导出
摘要 目的了解转染VEGF-ASODN(血管内皮生长因子反义寡核苷酸)对胃癌细胞Survivin(生存素)表达、细胞生长的作用.方法人工合成硫代磷酸化VEGF-ASODN,转染胃癌细胞SGC-7901,用Western-blot法检测细胞Survivin蛋白表达量、用流式细胞仪检测转染后细胞凋亡情况、用MTT检测转染后细胞生存力、细胞生长曲线检测转染后细胞生长情况.结果转染VEGF-ASODN能降低细胞Survivin蛋白,与对照组比较差异有统计学意义(P<0.05),转染后细胞凋亡与对照组比较差异有统计学意义(P<0.05),能降低细胞的生存力及抑制细胞生长.结论VEGF-ASODN能抑制Survivin蛋白表达、抑制胃癌细胞生长、增加胃癌细胞的凋亡. Objective To observe the effects of VEGF antisense oligonucleotide on expression of survivin and growth in gastric cancer cells. Methods The VEGF-ASODN was synthesised artificially. After transfected with VEGF-ASODN, survivin protein was measured by Western-blot, apoptosis was detected by FCM, survival of cells was detected by MTI'. Growth of cells was evaluated by growth curve. Results Transfected with VEGF-ASODN, it reduced the expression of survivin remarkably, increased apoptosis and decreased the survival and the growth of the cells. Conclusion VEGF-ASODN can reduce the expression of survivin, suppress the growth and increase the apoptosis of gastric cancer cell.
出处 《昆明医学院学报》 2009年第6期31-34,共4页 Journal of Kunming Medical College
关键词 血管内皮生长因子反义寡核苷酸 生存素 胃癌细胞 VEGF-ASODN Survivin Gastric cancer cells
  • 相关文献

参考文献12

二级参考文献63

  • 1Yu Cheng Tang,Yu Li,Guan Xiang Qian Department of Biochemistry, Shanghai Second Medical University, Shanghai 200025, China.Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy[J].World Journal of Gastroenterology,2001,7(1):22-27. 被引量:33
  • 2李莉,谢晓恬,梁爱斌,廖雪莲,石苇,杨莉莉,陈凤翠.血管内皮生长因子在急性白血病细胞株的表达[J].中国小儿血液,2004,9(4):170-174. 被引量:6
  • 3苏长青.细胞凋亡的形态代谢特点及生物学意义[J].临床与实验病理学杂志,1996,12(4):346-348. 被引量:12
  • 4周爱儒,郑卫,邢德智,王富强,汤健,马大龙,朱国英,陈光慧.“分子搭桥术”基因治疗闭塞性血管病的实验研究[J].中华医学杂志,1996,76(9):662-666. 被引量:23
  • 5[1]Barinaga M. Designing therapies that target tumor blood vessels[J]. Science, 1997, 275 (5299): 482-484.
  • 6[2]Yoshikawa T,Tsuburaya A,Kobayashi O, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma[J]. Cancer Lett, 2000, 153 (1-2) : 7-12.
  • 7[3]Miyake H, Hara I, Yamanaka K, et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer[J]. Urology, 1999, 53 (2): 302-307.
  • 8[4]Chen CA, Cheng WF, Lee CN, et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasma correlation with patient survival[J]. Gynecol Oncol, 1999, 74 (2): 235-240.
  • 9[5]Brattstrom D,Bergqvist M,Larsson A, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients[J]. Anticancer Res, 1998, 18 (2A):1123-1127.
  • 10[6]Abendstein B,Daxenbichler G,Windbichcer G, et al. Predictive value of uPA, PAI-I, HER-2 and VEGF in the serum of ovarian cancer patients[J]. Anticancer Res, 2000, 20 (11B): 509-572.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部